Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Natera (NTRA) and Cryolife (CRY).
Natera (NTRA)
Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on Natera yesterday and set a price target of $27. The company’s shares closed yesterday at $20.83.
Massaro commented:
“We are positive on the announcement, which we think 1) further opens the spigot for pharma trials that are not using FFPE tumor-tissue; 2) provides NTRA with an add-on cancer revenue opportunity for clients that use the service; and 3) expands NTRA’s oncology database to include WES data. We think this is a big deal and will take time for investors to better understand. NTRA is one of our top picks for 2019 and trades at just 3.7x Street ’20 revs (below its peak of ~5x just 9 months ago). We reiterate our BUY rating and Street-high $27 PT. WES launch is a big deal. Natera will begin providing blood-based whole exome sequencing (WES) in 2H/19 to detect ~20,000 genes from a patient’s circulating tumor DNA. Note this is broader coverage than Guardant Health’s ~500 gene OMNI panel.”
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 18.0% and a 61.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Natera has an analyst consensus of Strong Buy, with a price target consensus of $24.75, which is a 18.8% upside from current levels. In a report issued on April 4, Robert W. Baird also reiterated a Buy rating on the stock with a $24 price target.
See today’s analyst top recommended stocks >>
Cryolife (CRY)
In a report released yesterday, Michael Matson from Needham maintained a Hold rating on Cryolife. The company’s shares closed yesterday at $30.48.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.2% and a 66.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Cryolife is a Moderate Buy with an average price target of $32.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
